New Blood Test to Provide Safe, Early Prenatal Genetic Screening
By LabMedica International staff writers Posted on 08 Apr 2014 |
Caption: The Materni T21 Plus early prenatal screening genetic test is performed noninvasively on a sample of the pregnant woman\'s blood (Image courtesy of Synapse Diagnostics).
A noninvasive blood test has been developed to enable safe early prenatal detection of fetal chromosome abnormalities such as in Down's syndrome as well as the more challenging detection of microdeletions.
Synapse Diagnostics (Hyderabad, India) now offers "Materni T21 PLUS", a highly accurate prenatal genetic blood test for specific chromosome conditions associated with birth defects. Conducted on blood collected from the mother as early as 10 weeks of pregnancy, genetic abnormalities in the fetus, such as Down's Syndrome and multiple other defects, can be detected early using accurate, cutting-edge technology – a state-of-the-art genomic DNA sequencing based test – providing a clear and precise result which can be easily interpreted. Materni T21 PLUS is the only test in the international market that detects not only abnormalities such as in Down's syndrome but also microdeletion type defects. Microdeletion type abnormalities are difficult to detect, such that parents and clinicians usually spend years after birth trying to diagnose them as underlying the child's symptoms. With this advanced test they can be detected early in pregnancy.
Dr. Samit Sekhar, Managing Director for Synapse Diagnostics India, commented, “Down’s syndrome is a naturally occurring chromosomal arrangement that has always been a part of the human condition, being universally present across racial, gender, or socioeconomic lines, and affecting approximately 1 in 800 live births, although there is considerable variation worldwide. Down's syndrome usually causes varying degrees of intellectual and physical disability in the baby and is associated with various other medical issues.”
The current, amniocentesis, test is not only performed late in pregnancy but is also invasive with a risk of miscarriage. Furthermore, in some cases it cannot definitively pick up the microdeletions. Materni T21 provides a noninvasive alternative for early screening that is safe for both mother and unborn child. With this technology doctors and parents can safely obtain accurate information very early, which also helps mitigate anxiety associated with more aggressive procedures or with the uncertainty of other blood tests that may give only probability-based results.
The Materni T21 Plus test is developed and validated by Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP-accredited and CLIA-certified molecular diagnostics laboratory based in San Diego (CA, USA).
Related Links:
Synapse Diagnostics
Synapse Diagnostics (Hyderabad, India) now offers "Materni T21 PLUS", a highly accurate prenatal genetic blood test for specific chromosome conditions associated with birth defects. Conducted on blood collected from the mother as early as 10 weeks of pregnancy, genetic abnormalities in the fetus, such as Down's Syndrome and multiple other defects, can be detected early using accurate, cutting-edge technology – a state-of-the-art genomic DNA sequencing based test – providing a clear and precise result which can be easily interpreted. Materni T21 PLUS is the only test in the international market that detects not only abnormalities such as in Down's syndrome but also microdeletion type defects. Microdeletion type abnormalities are difficult to detect, such that parents and clinicians usually spend years after birth trying to diagnose them as underlying the child's symptoms. With this advanced test they can be detected early in pregnancy.
Dr. Samit Sekhar, Managing Director for Synapse Diagnostics India, commented, “Down’s syndrome is a naturally occurring chromosomal arrangement that has always been a part of the human condition, being universally present across racial, gender, or socioeconomic lines, and affecting approximately 1 in 800 live births, although there is considerable variation worldwide. Down's syndrome usually causes varying degrees of intellectual and physical disability in the baby and is associated with various other medical issues.”
The current, amniocentesis, test is not only performed late in pregnancy but is also invasive with a risk of miscarriage. Furthermore, in some cases it cannot definitively pick up the microdeletions. Materni T21 provides a noninvasive alternative for early screening that is safe for both mother and unborn child. With this technology doctors and parents can safely obtain accurate information very early, which also helps mitigate anxiety associated with more aggressive procedures or with the uncertainty of other blood tests that may give only probability-based results.
The Materni T21 Plus test is developed and validated by Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP-accredited and CLIA-certified molecular diagnostics laboratory based in San Diego (CA, USA).
Related Links:
Synapse Diagnostics
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans